Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by University of Michigan
Sponsor:
Collaborators:
Quercegen Pharmaceuticals
Information provided by (Responsible Party):
Umadevi S. Sajjan, University of Michigan
ClinicalTrials.gov Identifier:
NCT01708278
First received: October 10, 2012
Last updated: February 12, 2014
Last verified: February 2014
  Purpose

Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA. Current therapies for COPD are only partially effective and may also have side effects. Although increasing evidence indicates that quercetin supplementation may be beneficial in treating COPD, key methodological issues have not been resolved. The overall objective of this study is to determine the dosage of quercetin supplementation, bioavailability of quercetin, safety, dose-response relationship and appropriate biomarkers which reflect clinical outcomes in patients with COPD that is necessary for conducting large clinical trials in this patient population.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Quercetin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Phase I/II Study to Determine the Safety and Efficacy of Quercetin in COPD Patients

Resource links provided by NLM:


Further study details as provided by University of Michigan:

Primary Outcome Measures:
  • Determine the plasma quercetin levels in COPD patients following supplementation with quercetin [ Time Frame: One week in Phase I safety study and Four weeks in Phase II study ] [ Designated as safety issue: Yes ]
    Eligible COPD subjects will be supplemented with quercetin for one or four weeks and plasma quercetin levels will be measured prior to and after supplementation with quercetin or placebo. Safety of quercetin supplementation will also be determined based on blood and pulmonary function tests


Secondary Outcome Measures:
  • Determine the effects of quercetin supplementation on the markers of oxidative stress in COPD subjects [ Time Frame: 4 weeks supplementation ] [ Designated as safety issue: Yes ]

    Oxidative stress markers will be measured prior to and after quercetin or placebo supplementation

    • Protein carbonyls and nitrotyrosines
    • reduced glutathione
    • malondialdehyde.

  • Determine the effects of quercetin supplementation on the markers of inflammation in COPD subjects [ Time Frame: 4 Weeks supplementation ] [ Designated as safety issue: Yes ]

    Sputum and blood levels of markers of inflammation will be measured prior to and after supplementation with placebo or quercetin

    • IL-6
    • IL-8
    • sICAM-1
    • CD40L
    • CC16
    • PARC/CCL18
    • surfactant D protein
    • C-reactive protein in blood only


Estimated Enrollment: 102
Study Start Date: February 2014
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: sugar chew
contains 350 mg of vitamin C and 10 mg niacin
Drug: Quercetin
COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take Placebo containing 350 mg of vitamin C and 10 mg niacin or one of the two doses of quercetin twice a day for 4 weeks
Other Name: QB3C without folic acid
Active Comparator: Quercetin 1
Quercetin highest tolerated dose (to be determined)contains 350 mg vitamin C and 10 mg niacin
Drug: Quercetin
COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take Placebo containing 350 mg of vitamin C and 10 mg niacin or one of the two doses of quercetin twice a day for 4 weeks
Other Name: QB3C without folic acid
Active Comparator: Quercetin 2
Quercetin 500 mg containing 350 mg vitamin C and 10 mg niacin
Drug: Quercetin
COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take Placebo containing 350 mg of vitamin C and 10 mg niacin or one of the two doses of quercetin twice a day for 4 weeks
Other Name: QB3C without folic acid

Detailed Description:

In our preclinical study, we have demonstrated that 4 fold increase in plasma quercetin levels significantly decreased lung inflammation and prevented progression. Clinical studies in healthy volunteers 4 fold increase in plasma quercetin levels (0.22 to 1 µM) could be achieved by supplementing with 500mg of quercetin/day. However, safety of quercetin supplementation and quercetin dose required to achieve 4 fold increases in plasma quercetin levels in 'at-high-risk' COPD population is yet to be established. This study involves two phases; the first phase examines the safety of quercetin supplementation in subjects with chronic obstructive pulmonary disease (COPD) and the second phase determines the efficacy of quercetin in COPD patients. In this study, we will enroll COPD patients with mild to moderate disease between the age group of 40 to 65 years. During the first phase, we will enroll a total of 9 patients to examine the tolerance and safety of three doses of quercetin (500, 1000 and 2000 mg/day) in a dose escalation manner. First cohort consisting of three subjects will receive placebo or 500 mg of quercetin per day for one week and the safety of quercetin supplementation will be assessed by monitoring adverse events and any changes in outcomes of blood test that include complete blood counts (CBC)and comprehensive metabolic panel prior to after supplementation. If this dose is safe and tolerated, second cohort of 3 subjects will receive placebo or 1000 mg of quercetin per day quercetin for one week and again safety will be assessed. If the dose is safely tolerated, the third cohort will receive either placebo or 2000 mg of quercetin per day for a week and the safety will be assessed. Based on this initial study, we will choose the highest quercetin dose tolerated with no adverse events and the dose (500 mg of quercetin per day) that was found to increase plasma quercetin levels by 4 fold over baseline in healthy volunteers to examine the efficacy of quercetin in reducing inflammatory and oxidative stress markers and improving lung function in COPD subjects. In the second phase, we will enroll a total of 75 subjects and randomized into three arms; placebo (15 subjects) or one of the two doses of quercetin (30 subjects per arm). All enrolled subjects will be asked to avoid quercetin rich foods throughout the study period. One week after enrollment (run-in), subjects will be either supplemented with either placebo or one of the two doses of quercetin for 4 weeks. All participants will be blinded for study agents. Plasma and sputum quercetin levels, lung function, and markers of oxidative stress and inflammation will be determined at the start of the study (following run-in period), at the end of 4 weeks treatment period.

  Eligibility

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects diagnosed with mild to moderate COPD (GOLD stage I, II and III)-
  • 10 pack-year smoking history or greater and ceased to smoke at least for 2 months prior to recruitment
  • Subjects taking H2 antagonists, Imodium or loratadine and willing to stop during the study period

Exclusion criteria:

  • COPD subjects with >80% or <35% predicted
  • Current smokers
  • Known allergy/sensitivity to quercetin
  • Subjects with primary diagnosis of asthma
  • Upper respiratory tract infection within two weeks of the screening visit
  • Acute bacterial infection requiring antibiotics within two weeks of screening
  • Emergency treatment or hospitalization within one month of screening
  • Pregnant or lactating mothers
  • Women who don't consent to take pregnancy test
  • Unwillingness to stop flavonoid supplementation
  • Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener
  • Daily oral steroid treatment, warfarin, cyclosporine (neural, sandimmune), digoxin, fexofenadine, paclitaxel, diltiazem, saquinavir, selected chemotherapeutic agents (etoposide, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), protease inhibitors (amprenavir, indinavir, nelfinavir), verapamil, oral glucocorticoids, erythromycin, quinidine
  • Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period
  • Lung cancer history or undergoing chemo- or radiation therapy
  • Inflammatory bowel disease
  • Child bearing age, who are unwilling to use adequate contraception or abstain during the course of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01708278

Contacts
Contact: Fernando J Martinez, M.D. 734-763-2540 fmartine@umich.edu

Locations
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Fernando Martinez, M.D.    734-763-2540    fmartine@umich.edu   
Principal Investigator: Fernando J Martinez, M.D.         
Sub-Investigator: Umadevi S Sajjan, Ph.D.         
Sub-Investigator: MeiLan Han, M.D.,         
Sponsors and Collaborators
University of Michigan
Quercegen Pharmaceuticals
Investigators
Principal Investigator: Fernando J Martinez, M.D. University of Michigan
  More Information

Publications:

Responsible Party: Umadevi S. Sajjan, Assistant Professor, University of Michigan
ClinicalTrials.gov Identifier: NCT01708278     History of Changes
Obsolete Identifiers: NCT02013440
Other Study ID Numbers: HUM000061735, R21AT007357
Study First Received: October 10, 2012
Last Updated: February 12, 2014
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by University of Michigan:
COPD
Emphysema
chronic bronchitis
Quercetin
flavonoids

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases
Quercetin
Antioxidants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 21, 2014